🇺🇸 FDA

Company profile · Sponsor

BridgeBio

BridgeBio Oncology Therapeutics

BBOT · NYSE pharma SOUTH SAN FRANCISCO, CA, USA
Pipeline
24
Drugs
1
Patents
1

Quick answer

BridgeBio (BBOT) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 1 patent to this profile..

Company facts

Ticker BBOT
Exchange NYSE
Company type pharma
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001869105

Pipeline (24)

Search pipeline →

  1. AG10

    BridgeBio

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    phase 3 small molecule terminated

    1 trial

  2. ALXN2060

    BridgeBio

    Symptomatic Transthyretin Amyloid Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  3. Acoramidis

    BridgeBio

    Amyloidosis

    phase 3 small molecule active

    3 trials

  4. Acoramidis

    BridgeBio

    Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

    phase 3 small molecule terminated

    1 trial

  5. Acoramidis (AG10)

    BridgeBio

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 3 small molecule active

    1 trial

  6. Acoramidis (AG10)

    BridgeBio

    Amyloidosis in Transthyretin (TTR)

    phase 3 small molecule active

    1 trial

  7. BGJ398

    BridgeBio

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  8. Encaleret

    BridgeBio

    Autosomal Dominant Hypocalcemia Type 1 (ADH1)

    phase 3 small molecule active

    1 trial

  9. Encaleret

    BridgeBio

    Autosomal Dominant Hypocalcemia (ADH)

    phase 3 small molecule active

    2 trials

  10. Infigratinib

    BridgeBio

    Upper Tract Urothelial Carcinomas

    phase 3 small molecule terminated

    1 trial

  11. Infigratinib 0.25 mg/kg/day

    BridgeBio

    Achondroplasia

    phase 3 small molecule completed

    1 trial

  12. infigratinib 0.128 mg/kg/day

    BridgeBio

    Hypochondroplasia

    phase 3 small molecule active

    1 trial

  13. AG10

    BridgeBio

    Familial ATTR-CM (ATTRm-CM, or FAC)

    phase 2 small molecule completed

    1 trial

  14. AG10

    BridgeBio

    Amyloid Cardiomyopathy

    phase 2 small molecule active

    1 trial

  15. BGJ398 (infigratinib)

    BridgeBio

    Advanced Cholangiocarcinoma

    phase 2 small molecule terminated

    1 trial

  16. Infigratinib

    BridgeBio

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

  17. Infigratinib

    BridgeBio

    Achondroplasia

    phase 2 small molecule active

    1 trial

  18. Infigratinib 0.016 mg/kg

    BridgeBio

    Achondroplasia

    phase 2 small molecule completed

    1 trial

  19. Infigratinib is provided as a single dose of minitablets for oral administration

    BridgeBio

    Achondroplasia

    phase 2 small molecule active

    1 trial

  20. PTR-01

    BridgeBio

    Recessive Dystrophic Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial

  21. VT30

    BridgeBio

    Venous Malformation

    phase 2 small molecule terminated

    1 trial

  22. encaleret

    BridgeBio

    Post-Surgical Hypoparathyroidism

    phase 2 small molecule completed

    1 trial

  23. AG10 oral tablet

    BridgeBio

    Amyloid Cardiomyopathy, Transthyretin-Related

    phase 1 small molecule completed

    1 trial

  24. BBO-10203

    BridgeBio

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. acoramidis hydrochloride

    ATTRUBY

    ORAL approved

Patents (1)

Search patents →

  1. US 12427111

    Lipid nanoparticles

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is BridgeBio?

BridgeBio (BBOT) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 1 patent to this profile..

What pipeline programs does BridgeBio sponsor?

We track 24 ClinicalTrials.gov-linked programs for BridgeBio, including AG10 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does BridgeBio company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.